Belantamab Mafodotin,Pomalidomide,Dexamethasone
GSK
['belantamab', 'mmsm']
aa6: mpfs for belantamab vs pd was 11 vs 7 months with hr of 1.03
mos for belantamab and pd was 21 months with hr of 1.14
death secondary to progressing was 26% and 22% respectively #mmsm #myeloma #medtwitter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter